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Serial liver function tests (aspartate amino transferase–AST, alanine amino trans-
ferase–ALT and total bilirubin) were undertaken in patients admitted to controlled
clinical trials for the treatment of tuberculous meningitis and pulmonary tubercu-
losis. In patients with tuberculous meningitis, daily treatment with isoniazid 20
mg/kg in addition to rifampicin 12 mg/kg resulted in a significant increase in the
activities of both AST and ALT; there was no appreciable change with regimens
containing isoniazid 12 mg/kg. In two studies on pulmonary tuberculosis, there
was a significant increase in the activities of both enzymes following 2 or 3 months
of treatment with daily streptomycin, isoniazid and pyrazinamide with or without
rifampicin. No appreciable differences were observed between patients who re-
ceived rifampicin and those who did not and also between slow and rapid acetylators
of isoniazid.Serum total bilirubin showed a significant decrease following treat-
ment for 2 months with a daily regimen containing rifampicin in patients with tuber-
culous meningitis and also in those with pulmonary tuberculosis.A c mparison of
patients who developed jaundice during treatment with anti-tuberculosis drugs and
others who had jaundice presumably due to infective hepatitis revealed lower mean
values for total bilirubin, AST and ALT in the former group (by 48–64%) than in
the latter (P <0.02). There was, however, considerable overlap between the two
groups in the distributions of all parameters.
A recent report from the Tuberculosisand rifampicin, being 16-39 per cent in
Research Centre (TRC), Madras gavechildren with tuberculous meningitis and
the incidence of hepatitis, nearly always2-8 per cent in those with pulmonary
with jaundice, in patients in clinical trialsuberculosis. Further, hepatitis in those
of the treatment of tuberculous meningitisrece ving rifampicin occurred more often
and of pulmonary tuberculosis with re-in slow than in rapid acetylators. Liver
gimens containing isoniazid, rifampicin.function tests were undertaken routinely
streptomycin and pyrazinamide1. Th in patients admitted to these studies, and
incidence was high in patients treatedthis report presents the findings of these
with daily regimens containing isoniazidnvestigations.
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Material & Methods Studies and regimens :
These studies were undertaken in
south Indian tuberculous patients usually
drawn from the poorest sections of the
population of Madras City. Tuberculosis
was diagnosed on the basis of clinical
and biochemical findings in cerebrospinal
fluid in patients with tuberculous menin-
gitis, and on results of direct smear and
culture examination of sputum from those
with pulmonary tuberculosis.
Children aged 1-12 yr were admitted
to the studies on tuberculous meningitis
while patients aged 12 yr or more were
admitted to the clinical trials on pulmo-
nary tuberculosis.
(i) Tuberculous meningitis–The regi-
mens and dosages of drugs employed
during an initial intensive phase of 2
months are listed in Table I. Further,
in ll studies, the children were treated
for 10 more months with daily ethambutol
(17.5 mg/kg) and isoniazid (12 mg/kg);
patients admitted to study I received, in
addition, streptomycin (40 mg/kg) twice
weekly from the 3rd to the 6th month.
Almost all children received phenobar-
bitone 3-5 mg for varying periods and
all received steroids.
(ii) Pulmonary tuberculosis–The regi-
mens and dosages of drugs employed in
the two studies on pulmonary tuberculosis
Table I. Studies, regimens and dosages of drugs

















R (12 mg/kg), S (40 mg/kg) and H (20 mg/kg) daily for
2 months
          do            but with H 12 mg/kg
                                do                                  plus Z 30 mg/kg
do except that R was given twice
weekly
Pulmonary TB
R (12 mg/kg), S (0.75 g), H (400 mg) and Z (40 mg/kg)
daily for 2 months followed by S (0.75 g), H (15 mg/kg) and
Z (70 mg/kg) twice weekly for 3 months
                                do                                       except that the twice weekly
phase was for 5 months
               do                but without R
R (12 mg/kg), S (0.75 g), H (400 mg) and Z (35 mg/kg)
daily for 3 months
                   do                  plus S (0.75 g), H (15 mg/kg)
and Z (70 mg/kg) twice weekly for 2 months
                  do                  but without R
R, rifampicin; S, streptomycin; H, isoniaxid; Z, pyrazinamide
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are listed in Table I. Further, half the
patients admitted to study I, selected at
random, received prednisolone 20 mg
thrice a day during the first week; the
dose was then tapered off over the next
7 wk.
Determination of serum aspartate
aminotransferase (AST) and alanine ami-
notransferase (ALT) activities2, and serum
total bilirubin concentrations3 wa  under-
taken on admission, at 1 and 2 months
and at the end ofchemotherapy in patients
with tuberculousmeningitis ; and on
admission, at the end of the daily phase
of treatment and at the end of treatment
in those with pulmonary tuberculosis.
These tests and the determination of
alkaline phosphatase (AP) activity4 were
also undertaken in patients with symp-
toms suggestive of hepatic toxicity. The
acetylator phenotype of patients admitted
to study I of pulmonary tuberculosis
was determined by methods described
earlier5,6.
The differences between the mean
values within each series were tested by
t-test (paired), while t-test (unpaired)
was employed for testing the differences
between the series.
Results
Tuberculous meningitis : The liver function
tests on admission and at 1 and 2 months
in patients for whom values at all the
3 ime points are available are presented
in Table II (values at the end of treatment
have not been presented due to paucity
of numbers; moreover, jaundice occurred
al os  always during the initial intensive
phase of treatment for 2 months when
rifampicin was administered as one of
the drugs ).
There was a significant increase in
the activities of both the aminotrans-
ferases following daily treatment for 1
month with the 2 RSH (high), regimen
(P < 0.04). There was a slight fall there-
Table II. Liver function tests during treatment in children with tuberculous meningitis
Regimen
Geometric mean values in serum according to month of
determination
Total AST ALT Total bilirubin
patients (Karmen units) (Karmen units) (µmoles/l)*
0 1 2 0 1 2 0 1 2
month month months month month months month month months
2RSH (high)7 16 21.5 32.4 29.6 12.7 21.6 18.3 – – –
2RSH7 35–38 22.2 23.3 24.0 6.6 10.5 10.8 6.7 6.8 5.1
2RSH7 12–17 29.3 22.4 24.6 8.7 13.0 12.4 6.2 6.8 4.4
2R2SHZ7 52–55 28.3 24.2 28.2 12.6 14.1 16.1 5.1 5.1 5.5
*17.1 µmoles/l = 1 mg/dl
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after and the mean values at 2 months
were not significantly different from
those on admission. The changes in the
activities of the two enzymes during 2
months of treatment were minor with
the other three regimens. Serum bilirubin
concentrations were not determined in
patients admitted to the 2 RSH (high)7
regimen; with the other 3 regimens the
mean values at 1 month were similar to
those on admission. The mean concen-
trations at 2 months, however. were
about 24 and 29 per cent lower than those
on admission with the two daily regimens
(P=0.02 and 0.08, respectively).
Pulmonary tuberculosis :
Study I–Of the total of 683 patients
admitted to the study, test results at all
3 points (0, 2 and 5/7 months) were avail-
able in 616; the findings are presented in
Table III.
Two months of daily treatment re-
sulted in a significant increasein the
activities of both the aminotransferases
with all regimens (P<0.001). The mean
activities of both enzymes at the end of
treatment, while similar to those at the
end of the daily phase, were higher than
those before start of treatment (P<0.001)
for all regimens. At 2 months (end of
daily phase),serum AST levels of 40
Karmen units or more were encoun-
tered in 32 of 312 rifampicin patients
and 18 of 304 non-rifampicin patients
(P=0.07), while similarly elevated ALT
levels were observed in 13 rifampicin and
5 non-rifampicin patients (P=0.1).
The mean total bilirubin concentra-
tion at 2 months was about 15 per cent
lower than the pre-treatment value in
the rifampicin series (P=0.02); subse-
quent twice weekly treatment, however,
resulted in a significant increase, and the
mean value at the end of treatment was
about 29 per cent higher than on admis-
sion (P<0.001). In the non-rifampicin
series, the mean value at 2 months was
similar to that on admission; however,
the value at the end of treatment was
about 32 per cent higher than on admis-
sion (P<0.001).
Table III. Liver function tests during treatment in patients with pulmonary tuberculosis-study I
Regimen
Geometric mean values in serum according to month of
determination
Total AST ALT Total bilirubin
patients (Karmen units) (Karmen units) (µmoles/l)
0 2 5/7 0 2 5/7 0 2 5/7
month months months month months months month months months
2 RSHZ7/3 SHZ2 159 15.9 21.6 22.4 8.9 12.0 12.3 5.3 4.3 6.7
2 RSHZ7/5 SHZ2 153 16.4 22.3 20.8 9.0 12.0 11.9 5.1 4.8 6.7
Rifampicin regimens312 16.1 21.9 21.6 8.9 12.0 12.0 5.2 4.4 6.7
2 SHZ7/5 SHZ2 304 15.4 19.6 18.2 8.6 12.1 11.0 5.3 5.5 7.0
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The mean serum values of AST, ALTlower than the pre-treatment value in
and total bilirubin were similar in thethe rifampicin series (P<0.001) whereas
rifampicin and the non-rifampicin patientshe two values were similar in the non-
before start of treatment. At 2 months,rifampicin series. Subsequent twice weekly
the mean total bilirubin concentrationtreatment for 2 months resulted in a signi-
was lower (P<0.001) and the meanfic t increase ranging from 21-27 per
AST activity higher (P=0.03) in thecent in both series, and the mean values
rifampicin series than in the non-rifam-at the end of treatment were 8 per cent
picin series. At the end of treatment, thehig r in patients in the 3 RSHZ7/2SHZ2
mean total bilirubin and ALT valuesregimen (P=0.08) and 14 per cent higher
were similar in the two groups while thein the non-rifampicin series (P<0.01)
mean AST activity was higher in thethan on admission.
rifampicin series than in the non-rifampicin
series (P=0.05).
Study II–Three months of daily treat-
ment (results not tabulated) resulted in a
significant increase, ranging from 42-80
per cent, in the activities of both amino-
transferases with all regimens (P<0.001).
The mean values for both the enzymes
at 5 months were, however, 25-40 per
cent higher than those on admission
in both the rifampicin and the non-rifam-
picin series (P<0.001 for both).
The mean total bilirubin concentra-
tion at 3 months was about 14 per cent
Acetylator phenotype and liver function
tests : The influence of acetylator pheno-
type on the hepatic function was also
examined in the first study on patients
with pulmonary tuberculosis (Table IV).
The proportions of slow acetylators
among the 312 rifampicin and 304 non-
rifampicin patients were 57 and 59 per
cent, respectively. The mean activities
of AST and ALT were similar in slow
and rapid acetyrators in both the rifam-
picin and the non-rifampicin series at
0, 2 and 5/7 months. In the rifampicin
series, the mean serum total bilirubin
concentration at 2 months was similar
Table IV. Liver function tests in slow and rapid acetylators of isoniazid
Geometric mean values in serum according to month of
determination
Regimen Inactivator Total AST ALT Total bilirubin
status patients (Karmen units) (Karmen units) (µmoles/l)
0 2 5/7 0 2 5/7 0 2 5/7
month mouths months month months months month months months
Both
rifampicin Slow 177 15.6 22.9 20.7 8.8 13.0 11.2 5.0 5.1 6.5
regimens Rapid 135 16.8 20.8 22.8 9.1 10.8 13.3 5.5 3.8 6.8
Non-
rifampicin Slow 178 15.5 20.1 19.1 8.3 10.5 13.7 5.1 5.1 6.7
regimen Rapid 126 15.3 18.9 19.7 9.0 12.4 11.4 5.5 5.6 7.2
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to that on admission in slow acetylators;
in rapid acetylators, however, the mean
value at 2 months was about 31 per cent
lower than that on admission (P<0.001).
In the non-rifampicin series, the mean
values at 2 months were similar to those
on admission in both slow and rapid
acetylators. Subsequenttwice-weekly
treatment resulted in an appreciable in-
crease in patients of both phenotypes in
both the rifampicin and the non-rifam-
picin series. At the end of treatment, the
mean total bilirubin values were fairly
similar in both phenotypes in both the
rifampicin and the non-rifampicin series,
and 25-31 per cent higher than the res-
pective pre-treatment values (P<0.05).
Comparison between the two groups of
hepatitis patients : The liver function
tests were also undertaken during episodes
of hepatitis. These tests were done only
once (on diagnosis) in some patients and
more than once in the rest. During appro-
ximately the same period as the second
study on pulmonary tuberculosis was in
progress, a number of staff members or
their relatives (who were not receiving
any anti-tuberculosis drugs) had liver
function tests at the TRC because of
jaundice. Assuming that hepatitis in
tuberculous patients during treatment
is likely to be drug-induced, and that in
the other group, it is likely to be infective
hepatitis, a comparison of the various
liver function tests was undertaken and
the means are presented in Table V. In
th  case of subjects with two or more
det rminations, the set of values farthest
from normal was chosen (the differences
were of the same order when the values
obtained at the first determination were
compared).
The mean total bilirubin concentra-
tion was 48 per cent lower in tuberculosis
Table V. Liver function tests in patients with probable infective hepatitis alone and those who

























patients who developed jaundice than
in those with hepatitis alone (P=0.02).
Concentrations of greater than 35 µmoles/
I (2 mg/dl) were observed in 18 (55%)
of 33 patients in the former and 20 (80%)
of 25 patients in the latter. The mean
AST value was 51 per cent lower (P<0.01)
and the mean ALT value 64 per cent
lower (P<0.001) in tuberculosis patients
with jaundice than in those with infective
hepatitis alone. AST values of greater
than 200 units were encountered in 15
and 56 per cent respectively in the two
groups (P<0.01), and the proportions
of patients with similarly elevated ALT
values were 24 and 60 per cent, respec-
tively (P=0.01). The mean ratio of ALT
to AST was 0.99 in patients with tuber-
culosis and jaundice and 1.36 in those with
jaundice alone (P=0.05), and the pro-
portion of patients with a ratio of 1 or
more was 52 per cent in the former and
76 per cent in the latter (P=0.1). The
mean alkaline phosphatase values were
the same in the two groups. The pro-
portion of patients with values above
normal ( >14 KA units) was 37 per cent
in tuberculosis patients with jaundice
and 48 per cent in those with jaundice
alone; values greater than 25 units were
observed in 0 and 12 per cent respectively
in the two groups (P>0.2).
direct toxic effect and not a hyper-sensi-
tivity mechanism was responsible.1 Hepa-
titis during treatment with anti-tuber-
culosis drugs is also unlikely to be of
the cholestatic type as none of the patients
who developed hepatitis had a serum
alkaline phosphatase value greater than
25 KA units; marked elevation of the
activity of this enzyme, depending upon
the drug and its dosage, is usually seen
in d ug-induced cholestatic hepatitis7.
Two months of daily treatment with
regimens containing rifampicin caused a
significant decrease in the serum total
bilirubin concentrations in patients with
pulmonary tuberculosis as well as those
with tuberculous meningitis; no such
decrease was observed in patients who
did not receive this drug. Other worker8,9
have observed that daily administration
of rifampicin caused an initial increase
in the serum bilirubin levels followed
by a return to normal limits within 7 days
when treatment wascontinued:the
initial increase was attributed to the
competition between the two compounds
for uptake and/or biliary excretion.
Rifampicin, like phenobarbitone, is a
potent inducer of the hepatic microsomal
enzyme system, and phenobarbitone has
been shown to cause a decrease in the
total bilirubin levels, particularly in infants
Discussion with neonatal jaundice, by induction of
the hepatic glucuronidase which converts
free bilirubin to conjugated bilirubin10.
It is possible that prolonged daily adminis-
tration of rifampicin exerts a similar effect
and that bilirubin is cleared from serum
through conjugationand subsequent
biliary excretion. The decrease in total
bilirubin concentration during rifampicin
treatment was, however, observed in only
were reintroduced, suggesting that athe rapid acetylators of isoniazid; this
Hepatitis, nearly always with jaundic ,
occurred fairly frequently during daily
treatment with regimens containing rifam-
picin and isoniazid in our patients, and
the incidence was appreciably higher
in slow than in rapid acetylators of so-
niazid1. Hepatitis recurred in only a
small proportion of patients when d ugs
Raji Swamy et al 555
556 Liver function tests during treatment of TB
is an unexpected finding and it is not
known whether isoniazid or any of its
metabolites influence the hepatic bilirubin
clearance.
A significant increase in the activities
of both aminotransferases was observed
during the initial stages of treatment;
however, the differences between the
rifampicin and the non-rifampicin series
of patients were minor. The activities of
the two enzymes were also similar in
slow and rapid acetylators in both the
rifampicin and the non-rifampicin series.
Lack of difference in the aminotrans-
ferase activities between the two pheno-
types before, during and at the end of
chemotherapy was also observed in an
earlier study of the treatment of pulmo-
nary tuberculosis with once-weekly regi-
mens containing streptomycin and a
slow-release formulation of isoniazid at
our Centre11, in Singapore patients during
treatment with twice weekly and once
weekly regimens of isoniazid and rifam-
picin12 and in Hong Kong patients during
treatment with a twice weekly regimen
of isoniazid, streptomycin and pyrazina-
mide13. Hepatitis tended to occur fairly
early during treatment inour studies
(most occurred within a month of the
start of treatment in the second study
on pulmonary tuberculosis)1 and it is
possible that the enzyme levels had
stabilized by the time their activities
were routinely determined, namely at 1
month in patients with tuberculous menin-
gitis and at 2 or 3 months in patients with
pulmonary tuberculosis.
Marked elevation of the aminotrans-
ferase activities is usually observed in
patients with acute jaundice whereas
the elevation is less pronounced and
varies with the nature of the drug and its
dosage in patients with drug-induced
hepatitis; moreover, ALT levels usually
exceed those of AST in patients with
viral hepatitis while the converse has
been reported in patients with drug-
induced hepatitis7. In our studies, the
frequency ofthe occurrence of grossly
abnormal values for total bilirubin and
the two aminotransferases was greater in
patients with jaundice alone than in those
with tuberculosis and jaundice, while
the proportion of patients with ALT
values higher than AST values was only
slightly higher in patients with jaundice
alo e. However, there was a considerable
overlap between the two groups in the
distributions of all the parameters and
it was not possible to establish a criterion
to distinguish tuberculosis patients with
presumed drug-induced hepatitis from
those with presumed infective hepatitis
alone. In the absence of HBs Ag studies,
we could not prove that all the cases of
hepatitis that occurred during treatment
were due to the toxic effects of the drugs
e ployed, particularly as Madras region
in south India is endemic for infective
hepatitis. We suggest that. the biochemi-
cal tests normally used to assess liver
function are not capable of distinguish-
ing between the two groups of hepatitis
patients.
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